Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

BioSyent Inc. (V:RX)

Business Focus: Pharmaceuticals

Get the company report for the most recent outlook updated daily
Log in or join to add this stock to your watch list.

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEDI filings for RX within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Sep 12, 2019 09:00 ET
BioSyent Named to the Growth 500 Ranking of Canada's Fastest-Growing Companies for Seventh Consecutive Year
BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it has been named to the 31st annual Growth 500 ranking of Canada’s Fastest-Growing Companies by Canadian Business and Maclean’s.  The Growth 500 ranks Canada’s top private and...
Read full article
Aug 23, 2019 08:00 ET
BioSyent Releases Q2 and H1 2019 Results
BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today a summary of its financial results for the three and six months ended June 30, 2019. Key highlights include:  Second quarter (Q2) 2019 Net Revenues of $5,156,476 decreased by 13%...
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
0.17
--
--
Price to Sales - TTM
3.99
5.35
12.58
Price to Book - most recent quarter
3.35
2.92
2.74
Price to Cash Flow per share - TTM
17.30
6.72
12.18
Price to Free Cash Flow per share - TTM
18.81
9.34
18.59
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Aug 31, 201910,44410,210
Aug 15, 2019234-80
Jul 31, 2019314-4,774
See Short Report

Business Summary

Sector:  Healthcare Industry:  Pharmaceuticals

BioSyent Inc. is a specialty pharmaceutical company. The Company, through its subsidiary, BioSyent Pharma Inc., acquires or in-licenses and develops pharmaceutical products for sale in Canada and certain international markets. It has four business units: the Community and Women's Health Unit, which commercializes pharmaceutical products focused on improving family and women's health; the Hospital Business Unit, which sells pharmaceutical products to hospitals and hospital specialists; the International Pharmaceutical Unit, and the Legacy Business. Its products include FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Aguettant System and Cysview. FeraMAX 150 is an oral hematinic indicated for the prevention and treatment of iron deficiency anemia. Cathejell is indicated for surface anesthesia and lubrication for various procedures. RepaGyn helps relieve dryness and promotes healing of the vaginal mucosa. It also manufactures and markets Protect-It, a non-toxic product.

See business summary

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).
INK Staff's picture
Insights: From Fed patience to action $GWO.CA $HRX.CA $MAL.CA $YGR.CA $ECA $MACRO $HII.CA https://www.canadianinsider.com/blog/insights-fed-patience-action
May 28, 2019 12:22 pm
INK Staff's picture
Concerns that First Nations being exploited by professional pipeline protestors https://www.canadianinsider.com/blog/muir-concerned-first-nations-being-exploited-professional-pipeline-protestors #Cdnpoli #ABLeg $ECA $ARX.CA
Jan 10, 2019 10:50 am
INK Staff's picture
The INK Canadian Insider Index ends at 1,305.40 +5.79 (+0.45%) as $VRX.CA jumps 7.5% https://www.canadianinsider.com/node/7?menu_tickersearch=vrx #INKCIN $HII.CA
Jun 06, 2018 05:22 pm
INK Staff's picture
The INK Canadian Insider Index ends at 1,299.61 +8.64 (+0.67%) as $VRX.CA rallies 7.6% https://www.canadianinsider.com/node/7?menu_tickersearch=vrx #INKCIN $HII.CA $VRX
Jun 05, 2018 04:51 pm
Ted Dixon's picture
Insiders are selling pot-pharma like $WEED.CA https://www.canadianinsider.com/company?ticker=WEED and buying old skool like $VRX.CA $VRX https://www.canadianinsider.com/company?ticker=vrx
Jan 08, 2018 03:56 pm

Twitter

Search (past week) for $RX.CA RX.V